1. Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: A systematic review and meta-analysis. Syst Rev. 2006;1(1):1-12. doi: 10.1186/2046-4053-1-33
2. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: 10.1210/jc.2010-1692
3. Donadio F, Barbieri A, Angioni R, et al. Patients with macroprolactinaemia: Clinical and radiological features. Eur J Clin Invest. 2007;37(7):552-557. doi: 10.1111/j.1365- 2362.2007.01823.x
4. Joseph McKenna T. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf). 2009;71(4):466-469. doi: 10.1111/j.1365-2265.2009.03577.x
5. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: A prospective analysis. Obstet Gynecol Surv. 1989;44(9):684-685. doi: 10.1097/00006254-198909000-00016
6. Buchfelder M, Schlaffer SM, Zhao Y. The optimal surgical techniques for pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101299. doi: 10.1016/j.beem.2019.101299
7. Jones PS, Swearingen B. Intraoperative MRI for Pituitary Adenomas. Neurosurg Clin N Am. 2019;30(4):413-420. doi: 10.1016/j.nec.2019.05.003
8. Bayrak A, Saadat P, Mor E, Chong L, Paulson RJ, Sokol RZ. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril. 2005;84(1):181-185. doi: 10.1016/j.fertnstert.2005.01.102
9. M. Kinoshita, H. Tanaka, H. Arita, Y. Goto, S. Oshino, Y. Watanabe, T. Yoshimine and YS. Pituitary-Targeted Dynamic Contrast-Enhanced Multisection. Am J Neuroradiol. 2015;36(May):904-908. doi: 10.3174/ajnr.A4220
10. Tosaka M, Nagaki T, Honda F, Takahashi K, Yoshimoto Y. Multi-slice computed tomography-assisted endoscopic transsphenoidal surgery for pituitary macroadenoma: A comparison with conventional microscopic transsphenoidal surgery. Neurol Res. 2015;37(11):951-958. doi: 10.1179/1743132815Y.0000000078
11. Buchfelder M, Schlaffer S. Imaging of Pituitary Pathology. Vol 124. 1st ed. Elsevier B.V.; 2014. doi: 10.1016/B978-0-444-59602-4.00011-3
12. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65(2):265-273. doi: 10.1111/j.1365-2265.2006.02562.x
13. Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011;25(6):885-896. doi: 10.1016/j.beem.2011.05.011
14. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study. Neurology. 2006;67(7):1225-1229. doi: 10.1212/01.wnl.0000238508.68593.1d
15. Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). 2017;234(22):3279-3297. doi: 10.1007/s00213-017-4730-6
16. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14(4):228-238. doi: 10.2165/00002018-199614040-00003
17. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518-2522. doi: 10.1210/jcem.84.7.5810
18. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008;159(4):11-14. doi: 10.1530/EJE-08-0365
19. Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12(3):153-157. doi: 10.1007/s11102-008-0134-2
20. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JAH. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 2009;70(1):104-108. doi: 10.1111/j.1365-2265.2008.03458.x
21. Devin JK, Lakhani VT, Byrd BF, Blevins LS. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract. 2008;14(6):672-677. doi: 10.4158/EP.14.6.672
22. Lafeber M, Stades AME, Valk GD, Cramer MJ, Teding Van Berkhout F, Zelissen PMJ. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. 2010;162(4):667-675. doi: 10.1530/EJE-09-0989
23. Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf). 2010;73(3):369-374. doi: 10.1111/j.1365-2265.2010.03827.x
24. Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014;99(1):90-96. doi: 10.1210/jc.2013-2254
25. Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169(3):359-366. doi: 10.1530/EJE-13-0231
26. Salvatori R. Dopamine agonist withdrawal in hyperprolactinemia: when and how. Endocrine. 2018;59(1):4-6. doi: 10.1007/s12020-017-1469-0
27. Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50-61. doi: 10.1007/s12020-017-1444-9
28. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia. N Engl J Med. 2003;349(21):2023-2033. doi: 10.1056/NEJMoa022657